Abstract
Implantable neuromodulation technologies rely on trial periods where a temporary lead is placed to assess therapeutic stimulation efficacy. Permanent replacements may then be implanted by removing temporary leads and implanting new leads connected to internal pulse generators (IPGs). However, transitioning from temporarily placed leads to permanent devices introduces additional surgical burden on patients, who commonly experience less efficacious therapy from their permanent leads compared to their trial stimulators. To address this, we developed the Injectrode, a needle-injectable trial lead which accommodates chronic therapeutic stimulation by 1) transcutaneous means and 2) through attachment to commercial and custom-made IPGs via connectors coined “Handshakes.”
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Neuromodulation: Technology at the Neural Interface
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
